<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 131 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page130.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=131">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 131 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 131</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=131"><img src="../thumb/131.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>100 / 2020-04                                                Cardio-Vascular Agents - 7.3.4 / 7.3.5 / 7.3.6
   Drug interactions: Poss.potent.of antihypertens. /meds.that have   trough conc.incr.signific.with concom. amiodarone, AUC incr.with   if not poss.admin.agent such as atrop.to counter incr.in vagal tone,
   hypotens.eff., steady state trough conc.of digox.incr.in hypertens.pts.,   concom. fluoxetine, concom.paroxetine incr.expos., hypotens. eff.  peri-op per., safety dur. long-term admin., ren.dysfunct., elderly, dis-
   incr.syst. bioavailabil. with cimetidine, rifampicin decr.syst. availabil.,   revers.& periph.vasoconstrict.eff. enhanc. by α-adrenorecept.stimu-  cont. grad.partic.in ischaem.heart dis., Prinzmetal’s ang., pulse rate
   eff.of insul.& oral hypoglycaem.incr., hydralazine & alcoh.incr.plasma   lat.agents., rifampicin decr.syst.availabil., steady state digox. trough   &lt;55 beats/min., early S&S of hypoglycaem.poss.mask., poss.dos.
   conc., synerg.with concom.diltiazem, hypotens.&/sev.bradycard.with   conc.incr.in hyperten.pts., incr.syst. bioavailabil. with cimetidine, incr.  reduct. of insul./antidiabet.meds., hyperthyroid. sympts. mask., con-
   meds. deplet.catecholamin./adrenerg.neuron block. agents, eff.dimin.  BP/imp.BP control. with concom.NSAIDs, hydralazine & alcoh. incr.   tact lense wear.due to reduc. lacrimat., where anaphylax.hist.pres.
   by ß-adrenorecept. stimulat. agents, hypotens.eff.revers.& periph. va-  plasma conc., bld.sugar reduc.eff.of insul.& oral hypoglycaem.enhanc.  pt.poss. more reactive to rep.challeng.with antigen.
   soconstrict. eff. enhanc.by a-& beta adrenorecept. stimulat.agents,   Drug interactions: Life threaten.conseq.with concom. hypoglycaem.
   incr.plasma lev.of both phenothiazin.& ß-blocks.if used concurr., incr.   TRANDATE, (Aspen Pharmacare: Pharma) Pharmacare [PWR]  agents/phenothiaz.& var. anti-arrhythmic agents, hypotens.effs.an-
   mean trough ciclospor.conc., poss.incr.AV conduct. time/ neg.inotrop.  Labetalol HCl.  tagon. by NSAID’s, effs.of insul.& sulphonylureas potent., poss.AV
   eff. with myocard.depress.incl. anti-arrhythm.  Indications: Rapid control of BP in sev.hypertens. incl.use in halo-  conduct.time potent.& negat. inoptrop. eff.with myocard.depress.
                                thane anaesthes.where hypotens. techniq.indicat.
   DILATREND, Pharmaco [PWR]    (S3) INJ. J/7.1.3/54. 100 mg/20 ml.  agents incl. anti-arrhythm.e.g disopyramide/procainamide/ lignocaine
                                                              & phenytoin, metabol.& pharmacokinet. poss.affect.by quinidine, sev
   Carvedilol                   771643-004: 5x20 ml, R1 847,03  bradycard. with meds.deplet.catecholamin.or adrenerg. neuron block.
   Indications: Essent.mild to mod.hypertens., adjunct in mild/mod./  Dosage: Adults: Receiv.in supine posit.avoid rais. pt.to upright posit.  agents., eff.dimin.by ß-adrenorecept. stimulat.agents, hypotens.eff.
   sev.mod.stable symptomat. HF of ischaem/cardiomyopath.origin,   for 3 hrs.aft.IV admin. Monit.BP & HR dur & aft.infus.  revers. & periph.vasoconstrict.eff.enhanc.by alpha-adrenorecept.
   adjunct.in longt. treatm.follow.uncomplic.MI with L.ventric. dysfunct.  Dil.200 mg: 200 ml NaCl/Dextr.BP to = 1 mg/ml. Admin.via vol.con-  stimulat.agents or those with mix. a-& beta adrenorecept.stimulat.
   (S3) TABS, 31/7.1.3/0198, 199, X/7.1.3/246  trol.infus.pump to facilit.accurat. dos.  propert., rifampicin decr.system.availabil., cimetid.incr. system. bio-
   833428-004: 6,25 mg, 30, R195,75  Rate of IV infus.2 mg (2 ml infus.sol.)/min.till satisfact. respon.& then   availabil., hydralazine & alcoh.incr. plasma conc.
   836354-001: 12,5 mg, 30, R204,11  stop. Effect.dos.usually within range of 50-200 mg. Dos.up to 300 mg
   788856-006: 25 mg, 30, R204,11  may be req.in phaeochromocyt.
   Dosage: Do not discont.abrubtly.  Hypotens.anaesthes: Induc.anaesth.with std agents & maint.with
   Hypertens: Adults: 25 mg once dly. Init:12,5 mg as sngl.dos.for 1st 2   halogen.inhalat.anaesthet. Recomm.start dos: 10-20 mg IV depend.on   7.3.5   Sympathetic nervous
   days. Combinat.with diuret. may also give desir.respons.  age & pts.condit. If aft.5 mins.satisfact.hypotens.not achiev.admin.in-
   Elderly: 12,5 mg once dly. If inadeq.dos may be titrat. at 2 wkly   crem.of 5-10 mg until desir BP obtain. As halogen.inhalat.anaesthet. &   blockers
   interv.up to 25 mg once dly/in div. dos.  Labetalol act synergistic.the halogen.inhalat.anaesthet. conc.should
   CHF: Take with food. Indiv. Dos of digox./diuret./ ACE inhibits to   not exceed 1-1,5% as profound BP falls poss.precipitat. Follow.inj.BP   A-LENNON RESERPINE, (Aspen Pharmacare: Pharma)
   be stabilis.prior to carvedilol initiat. Init.3,125 mg 2xdly x2 wks. If   can be quickly & easily adjust.by alt.halogen.inhalat.anaesthet. conc.   Pharmacare [P/S]
   tol.may be incr.at 2 wkly interv.to 6,25 mg 2xdly, folllow.by 12,5 mg   and/or adjust.table tilt. Mean durat.of hypotens. follow.20-25 mg is   Reserpine
   2xdly & thereaft.25 mg 2xdly. Incr.to high.dos.tol. by pt. Max.25 mg   50 mins. Hypotens. revers.by atrop.0,6 mg and discont.of halogen.   Indications: Mild to mod.hypertens.
   2xdly in pts.&lt;85 kg & 50 mg 2xdly in those &gt;85 kg. Bef.each dos.  inhalat.anaesthet. Non-depolaris.musc.relax.may be used when as-  (S3) TABS. B886
   incr.eval.pt.for sympts. of worsen.HF/vasodilat.& treat.accord.  sist./control.ventilat.reqd., IPPV. may furth.incr.hypotens.  760048-010: 0,25 mg, 28, R23,70
   if necess.                   Sev.hypertens.of pregn: Init.infus.20 mg/hr. Dos. may be doubl.ev-
   Left ventric.dysfunct.follow.MI: Indiv. Init. treatm. when   ery 30 min.until satisf.respons./ dos of 160 mg/hr reach.  Dosage: Indiv. Admin.with milk/food. Adults: 1 tab.dly for about 2 wks.
                                                              then reduc. to low. dos. need. maint.respons. Do not exceed recomm.
   pt.haemodynamic.stable & fluid retent. minimis.. Pt to receiv.  Contraindications: A-V block, pregn., asthma, follow.ac.MI
   ACE-inhibit.x48 hrs.at stable dos.dur.preceed.24 hrs. Start treatm.  where periph.vasoconstrict.suggest low card.output., cardiogen.  dos. Usual.used in combin. with diuret.to reduc.reqd.reserpine dos.
                                                              Contraindications: Depress.hist., act.pept.ulc., ulcerat.colit.,
   betw. day 3-21 post MI. Init.recomm.dos: 6,25 mg keep. pt.und.clos   shock, condits.assoc. with sev./prolong.hypotens./sev.bradycard.,   gallston., phaeochromocytoma, Parkinson’s dis., epilep., pts.undergo.
                st
   supervis.x3 hrs. Subseq.dos.if 1  dos. well tol.incr.to 6,25 mg 2xdly.  obstruct. airway dis.hist.  ECT, safety in pregn.& lactat.not est.
   x3-10 days. Reduc. dos. to 3,125 mg 2xdly.if intol.develops (ie.  Side effects: Postur.hypotens., confus., disorientat., bronchosp.,   Side effects: Nas.congest., CNS effs., GI disturbs., poss.precipit.
   bradycard. &lt;50 bpm/systol.BP &lt;80 mm Hg/fluid retent.). Discont.if   bld.sug.incr., bradycard.  bil.colic in pts.with gallston., breast engorgem., galactorrh., gynae-
   this reduc.dos.not tolerat. If well tolerat. dos. should again be incr.  Special precautions: Jaund.(discont.), asthma/ bronchosp., dia-  comast., decr.libido, impot., sod.retent., oed., incr.appet., mass gain,
   to 6,25 mg 2xdly. after 3-10 days. Subseq.up-titrat: If 6,25 mg 2xdly.   bet.mellit., in pts.on ther.requir. anaesth.admin.atrop.prior to induct.,   mios., dry mouth, sialorrh., thrombocytopen.purpura, flush./brady-
   well tol. incr.at 3-10 day interv.to 12,5 mg 2xdly and then 25 mg   digoxin resist.HF, monit.resp.funct.part.in pts.with known impairm.,   card./sev. depress. poss.lead.to suic./extrapyramid.effs.with high.
   2xdly. Max.recomm.dos: 25 mg 2xdly.  hypovolaem., compensat.physiolog. respons.to haemorrh.poss.  dos., resp.distress/cyanos./anorex./ hypotherm./ lethargy poss.in
   Contraindications: New York Heart Assoc.class IV decompen.HF   mask.dur anaesth.& close attent.to bld.loss/bld.vol.maintain.advis.  infts.whose mothers receiv. ther.prior to deliv.
   requir.IV inotrop.support, sev. heart dis., 2nd/3rd degr.heart block,   Drug interactions: Insulin/oral anti-diabet. agents, halothane
   part.heart block, sick-sinus syndr., sev./sinus bradycard., cardiogen.   eff.on BP incr.  Special precautions: Elderly/sev.debilit.pts., 7-14 days interv.betw.
                                                              last dos. & ECT commencem., arrhythm., MI, sev.card.damage, ren.
   shock, asthma/chron.obstruct.lung dis. with bronchospast.compon.,   VEDIBLOK, (Teva) Actavis [PWR]  insuff., allerg. condits., cross.placenta/pass.into breast milk, anaes-
   allerg.condits.involv. airways, metabol.acid., imp.hepat.funct., sev.   Carvedilol  thes., discont.at 1  signs of depress., adrenal./ other direct-act.sym-
                                                                     st
   hypotens., pregn.& lactat., safety in childr.not est.  Indications: Mild to mod.essent.hypertens., mild to mod.sta-  pathomimets.not to be giv. concom.except to antagon.A-Lennon Re-
   Side effects: Anaem., thrombocytopen., leukopen., card.fail.,   ble symptomat.HF of ischaem./ cardiomyopath.origin in conjunct.  serpine, ment.disords.poss.persist for wks. aft. ther. stopp., lact.intol.
   bradycard., hypervolaem., fluid overload, AV block, ang.pect., vis.  with std.ther.  Drug interactions: Reduc.eff.of indir.act. sympathomimets., enhanc.
   impairm., decr. lacrimat., eye irrit., GI disords., asthen., oed., pain,   (S3) TABS, 41/7.1.3/0126, 0127, 0128  effs with thiaz.diurets./ other antihypertens., excitat./hypertens.with
   incr.ALT/AST.GGT, hypersens.reacts., pneum., bronchit., URTI, UTI,   710958-001: 6,25 mg, 30, R68,02  MAOIs, card.arrhythm.with digital./quinidine, reduc. eff.with NSAIDs,
   incr.weight, hypercholesterolaem., imp.bld.gluc.contr. (hypergly-  710959-001: 12,5 mg, 30, R75,78  thiopentone/other CNS depress. effs.enhanc.
   caem., hypoglycaem.) in pts.with pre-exist. diabet., pain in extre-  710960-001: 25 mg, 30, R96,45
   mit., dizzin., headache, syncope, presyncope,paraesthes., depress.,   Dosage: Take aft.meals.
   depress. mood, sleep disords., ren.fail.& ren.funct. abnorm. in   Essent.hypertens: Adults: Init: 6,25 mg 2xdly. x1-2 wks., with
   pts.with diffuse vasc.dis.&/or underly. ren. insuffic., micturit.  maint.of 12,5 mg 2xdly OR Init. 12,5 mg once dly.x2 days with maint. 7.3.6   Direct-acting vasodilators
   disords., erect.dysfunct., dyspn., pulm.oed., asthma in predispos.  of 25 mg once dly.
   pts., wheez. in pts.with asthma & COPD, nas.congest., skin reacts.   Elderly: Init.12,5 mg once dly. If necess.incr.dos. as tol.at 2 wk interv.  HYPERPHEN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]
   incl.allerg.exanthema/dermatit./ urticar./ prurit./psoriat.& lichen   up to 25 mg once dly/in div. dos.
   plan.like skin les., hypotens., orthostat.hypotens., periph. circulat.   CHF in conjunct.with std.ther: Indiv. Init. 3,125 mg 2xdly x2 wks.  Hydralazine HCl.
                                                              Indications: Reduc BP in hypertens.
   disturbs., hypertens., urin. incontin. in women, alopec., sev.cutan.  then incr.to 6,25 mg 2xdly.x2 wks. Maint.& max.dos: 25 mg 2xdly in   (S3) TABS. M/7.1.3/39, 40.
   reacts, (toxic epiderm. necrolys., Stev.-Johns.syndr.)., due to   pts.&lt; 85 kg & 50 mg 2xdly in those &gt;85 kg.  731714-008: 10 mg, 100, R98,30
   ß-block.props.latent diabet. mellit.poss.manifest/manifest diabet.   Contraindications: Bronchosp., asthma, obstruct. airway dis.hist.,   731722-019: 50 mg, 100, R92,31
   aggrav. & bld.gluc.counter-regulat.inhibit.  bronchit., chron.resp. dis., 2nd/3rd degr.AV block, sev.bradycard.(&lt;50   731722-027: 50 mg, 500, R461,54
   Warnings and special precautions: Contr.CCF , ren.impairm.,   bpm), New York Heart Assoc.class IV decompen. HF requir.IV ino-  Dosage: Usual dos.: 100-200 mg dly.start.with 10-20 mg 2-4xdly
   1st contr.phaechromocyt.adeq.with alpha block. bef.init., in HF eval.  trop.support, cardiogen.shock, sick-sinus syndr.incl.sino-atrial block,   incr.grad.until desir.eff.obt. Max.300 mg dly.
   pt for worsen. sympts. bef.each incr.& treat accord., if ther. discont.   hepat. funct. impairm., metabol.acidos., periph.vasc.dis., Raynauds   Contraindications: Tachycard., hist of coron.dis., safety in pregn
   for long.than 2 wks.in HF recomm.ther.at 3,125 mg 2xdly.bef.up-titrat.  phenomen., allerg.condits.involv. airways, pregn., lactat., safety &   not est.
   in line with dos. recommendat., CHF pts.control.with digit./diuret.   effic.in childr. not est.  Side effects: CV effs., sweat., GI disturbs., postur. hypotens., con-
   &/ACE inhibit., before treat.L.ventric.dysfunct. follow. uncomplicat.  Side effects: Bld.dyscras., hypoglycaem., periph. oed., hypervolaem.,   junctivit., lacrimat., chill, fev., vertigo, flush., dyspn., malaise, musc.
   ac.MI pt.to be clin.stable & treat.with ACE inhibit.for &gt;48 preceding   fluid retent., dizzin., syncope, CNS effs., fatig., psychos., hallucinat.,   cramps, nas.congest., hepatit., loc.oed., urin.retent., CNS effs., par-
   hrs & dos. of ACE inhibit.be stable for &gt;24 preceding hrs., grad. dis-  paraesthes., periph.neuropathy, vis.disturbs., decr. tear product., blurr.  alyt.ileus, drug fev., skin rash., polyneurit., GI haemorrh., bld dyscr.,
   cont.in ischaem.heart dis.over 1-2 wks., pulse rate &lt; 55 beats/min.,   vis., ocul.pain, bradycard., total atrioventricul.block, aggravat. heart   ac.rheumat.state & disseminat. LE syndr.with chron.high dos.
   diab.mellit., obscure thyrotoxicos. sympts., monit.CHF pts.at risk of   dysfunct., Raynaud’s phenomenon, sev. periph. vasc.dis., periph.gan-  Special precautions: MAOI/TCA’s., reduc dos.in slow.acetylators,
   ren. funct. deteriorat., monit.pts.with COPD at init.& upward titrat.&   grene, CCF, hypotens., chest pain, haematur., orthostat. hypotens.,   anaesth., 50 mg strength cont.sucrose.
   discont.if any evid.of bronchosp. observ., contact lense wear.due to   bronchoconstrict.in asthma/bronchit./ other chron.pulm.dis., dyspn.,   Drug interactions: Adren.enhanc.card.acceler. eff., thiazide diu-
   reduc.lacrimat., periph. vasc.dis, periph.circulat.disords., Prinzmetal’s   GI disturbs., hepat. injury, allerg.skin reacts., revers.alopec., skelet.   ret.& ß-adrenerg.block.agents enhanc.hypotens.eff., ß-block.dimin.
   variant ang., 1-2 mg atrop.admin.IV may protect pt.against vagal influ-  musc. weakn.& cramps, myopathies, genit.oed., impot., oed., fev.,   card. accelerat. eff.
   enc., discont.48 hrs. prior to anaesth., monit.ECG & BP with concom.   hypercholesterolaem., sleep disords., headache, nas.congest., pain
   non-dihydropyrid.Ca antagon./ amiodarone/ other anti-dysrhythmics,   in limbs, aggravat. ren.dysfunct., diffic.in urinat., aggravat. psorias.  LONITEN, Pfizer [P/S]
   myocard. depress. agents, meds.deplet.catecholamin.or adrenerg.   Special precautions: 1st contr. pheochromocyt. adeq.with alpha-  Minoxidil.
   neurone block.agents., when terminat. both carvedilol & clonidine tog.  adrenocept. block. ther., contr.CHF 1 , clonidine transf., sev. rebound   Indications: Adjunct.therapy in sev.refract. hypertens. which has
                                               st
   withdr.carvedilol sev. days bef.grad.decr.clonidine,, monit.ciclospor.   hypertens.with concurr.clonidine if clonidine not discont.sev days   failed to respond to extens. multiple therapy.
   lev. aft. init.carvedilol & adj.dos.as appropr., monit. digox.lev.when   aft.withdr., digitalisat. maybe necess.with long-term beta-block.   (S4) TABS. N/7.1/165, 166.
   init., adjust./discont.carvedilol., hypersens. react.hist.& pts.undergo.  ther.if CCF likely to develop., avoid anaesthet. agents caus.myocard.  739235-001: 5 mg, 100, R587,98
   desensitis. ther., perm.discont.in pts.exper.sev.cutan.reacts., psorias.   depress./ concom. card.depress.Ca chann.block.e.g. verapamil &   739243-004: 10 mg, 100, R1 046,44
   hist.assoc.with ß-block.ther., contains lact. & sucrose.  diltiazem, monit.digox.lev.when adjust. carvedilol, signif.incr.SE incid   Dosage: Adults: Sngl./div.dos. 5-40 mg/day. Max: 100 mg/day. If
   Drug interactions: Poss.potent.of antihypertens. /meds.that have   with only margin. incr.in effic.if dos.&gt; 25 mg, pts.receiv. digit./ diu-  desir.diastol.reduct.&gt;30 mmHg div. dos.will minim.diurn.fluctuat.,
   hypotens.eff., bioavail.of concom. meds.transport.by P-Gp incr., bio-  ret.&/ACE inhibit.to be stabilis.bef. init. ther., in HF /vasodilat.eval.  Adjustm.made at interv.of 3 days or long. More rapid press.reduct.
   avail.modif.by concom. induc./inhibits.of P-Gp, synerg.with concom.   pt for worsen.sympts. bef. each incr.& treat accord., if ther.discont.   can be achiev.using contin.BP monit.& increment. dos.of 5 mg 6 hrly.
   diltiazem, concurr.use of phenothiaz.& ß-block. may result in incr.plas-  long. than 2 wks.in HF init.from start.point, reduc. diuret. dos.may as-  Pts.over 12 yrs: Init. 5 mg dly.as sngl./div.dos., then 5-10 mg in-
   ma levs.of both meds, eff. dimin.by ß-adrenorecept.stimulat.agents,   sist in managem.of vasodilat. sympts., do not incr.dos.until sympts.  crem.at 3-day interv.till 50 mg/day, then incr.by 25 mg/day to
   ß-agon. bronchodilat.eff.oppos., plasma conc.of oral ciclospor. incr.,   of worsen. HF/ vasodilat.are stabil., discont.48 hrs.prior to anaesth.   max.100 mg/day.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page130.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page126.html">126</a>&nbsp;&nbsp;&nbsp;<a href="page127.html">127</a>&nbsp;&nbsp;&nbsp;<a href="page128.html">128</a>&nbsp;&nbsp;&nbsp;<a href="page129.html">129</a>&nbsp;&nbsp;&nbsp;<a href="page130.html">130</a>&nbsp;&nbsp;&nbsp;<a href="page131.html">131</a>&nbsp;&nbsp;&nbsp;<a href="page132.html">132</a>&nbsp;&nbsp;&nbsp;<a href="page133.html">133</a>&nbsp;&nbsp;&nbsp;<a href="page134.html">134</a>&nbsp;&nbsp;&nbsp;<a href="page135.html">135</a>&nbsp;&nbsp;&nbsp;<a href="page136.html">136</a>
             </td>
             <td width="35%"><a href="page132.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page132.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
